Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (48 ops.)
Latest filing published 17 Aug 2026 for Royalty Pharma plc, €469k.
Filing timeline
BuySaleTerrance P. Coyne
Insider track record
Disclosed buys
2
Disclosed sells
48
Signal history
Closed purchases
Market purchases
2
Positive at T+90
0%
Median T+90
-17.0%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -14.4%Entry US$50.25 · Close at T+365 US$43.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Terrance P. Coyne: trading record in brief
Terrance P. Coyne is EVP & CFO of Royalty Pharma plc, the only company in a record of 60 filings published from June 2020 to August 17, 2026. Activity has clearly intensified: 3 filings in 2020, 10 in 2021, then 13 in 2025 and 27 in 2026.
Open-market sales number 48, worth EUR 47,648,640 in total with a median of EUR 583,881. The three largest are EUR 3,948,935 on February 3, 2026, EUR 3,695,530 on March 2, 2021 and EUR 3,643,296 on February 2, 2026. There are also 2 purchases, both on June 18, 2020: EUR 37,463 and EUR 36,214, or EUR 73,678, which is 4% of market trades. The rest: 5 share grants and 5 filings of another kind.
Over the last twelve months, 38 filings are recorded, 35 of them sales. They are published a median of 2 days after the trade.
At Royalty Pharma, 26 of Coyne's trades fall within 30 days of trades by Marshall Urist and 23 of George W. Lloyd's, in the same direction; James F. Reddoch shares 6, Christopher Hite and Mario Germano Giuliani 5 each.
Companies and markets linked to Terrance P. Coyne
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations60 total
9,230 shares@ US$58.58640.0016% mcap1.5% of flowClass A Ordinary SharesSEC:0001814876-26-000027:0
1,772 shares@ US$59.14150.0003% mcap0.3% of flowClass A Ordinary SharesSEC:0001814876-26-000027:1
11,002 shares0Class A Ordinary SharesSEC:0001814876-26-000025:0
64,399 shares@ US$53.97780.0098% mcap9.6% of flowClass A Ordinary SharesSEC:0001814876-26-000022:0
32,916 shares@ US$49.77840.0048% mcap4.5% of flowClass A Ordinary SharesSEC:0001814876-26-000018:0
1,875 shares@ US$49.77840.0003% mcap0.3% of flowClass A Ordinary SharesSEC:0001814876-26-000018:1
1,875 shares@ US$48.33180.3% of flowClass A Ordinary SharesSEC:0001814876-26-000016:0
32,916 shares@ US$48.33184.4% of flowClass A Ordinary SharesSEC:0001814876-26-000016:1
1,875 shares@ US$45.530.2% of flowClass A Ordinary SharesSEC:0001814876-26-000014:1
32,916 shares@ US$45.52874.2% of flowClass A Ordinary SharesSEC:0001814876-26-000014:0
10,429 shares@ US$47.010.9% of flowClass A Ordinary SharesSEC:0001814876-26-000012:1
1,292 shares@ US$46.670.1% of flowClass A Ordinary SharesSEC:0001814876-26-000012:2
583 shares@ US$47.010.0% of flowClass A Ordinary SharesSEC:0001814876-26-000012:3
22,487 shares@ US$46.67172.9% of flowClass A Ordinary SharesSEC:0001814876-26-000012:0
1,875 shares@ US$45.320.2% of flowClass A Ordinary SharesSEC:0001814876-26-000010:1
32,916 shares@ US$45.31654.1% of flowClass A Ordinary SharesSEC:0001814876-26-000010:0
26,626 shares0Class A Ordinary SharesSEC:0001814876-26-000008:0
108,759 shares@ US$42.848.3% of flowClass A Ordinary SharesSEC:0001814876-26-000006:1
19,076 shares@ US$43.291.5% of flowClass A Ordinary SharesSEC:0001814876-26-000006:2
5,843 shares@ US$42.080.4% of flowClass A Ordinary SharesSEC:0001814876-26-000006:3
6,195 shares@ US$42.840.5% of flowClass A Ordinary SharesSEC:0001814876-26-000006:4
1,087 shares@ US$43.290.1% of flowClass A Ordinary SharesSEC:0001814876-26-000006:5
102,581 shares@ US$42.083911.7% of flowClass A Ordinary SharesSEC:0001814876-26-000006:0
3,750 shares@ US$39.350.3% of flowClass A Ordinary SharesSEC:0001814876-26-000004:1
65,832 shares@ US$39.34847.2% of flowClass A Ordinary SharesSEC:0001814876-26-000004:0
25 of 60 declarations
